SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma reports loss of Rs 45.12 crore in Q2

08 Nov 2012 Evaluate

AstraZeneca Pharma India has reported results for second quarter ended September 30, 2012.

The company has reported a net loss of Rs 45.12 crore for the quarter ended September 30, 2012 as compared to a net profit of Rs 21.08 crore for the same quarter in the previous year. Total income of the company has decreased by 32.69% at Rs 101.02 crore for quarter under review as compared to Rs 150.08 crore for the quarter ended September 30, 2011.

AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.

Astrazeneca Pharma Share Price

8510.00 103.40 (1.23%)
22-Jun-2026 14:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1855.10
Dr. Reddys Lab 1301.40
Cipla 1415.30
Zydus Lifesciences 1073.85
Lupin 2342.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: